Pharvaris N.V. (PHVS) short interest & options flow
NASDAQThree weeks of converging data on PHVS have not reversed. The B of A Securities upgrade to Buy, published October 23, remains the anchor. Options positioning has stayed skewed toward calls, and the borrow market has loosened further since the earlier retail-attention spike. Why this matters: Pharvaris trades at $31.41, up 13.2% over the past week. The consensus among 11…
PHVS upgraded to Buy by B of A Securities as deucrictibant Phase 3 data reinforces HAE prophylaxis potential; analyst maintains $44 price target.
- Market cap
- $2.36B
- Next earnings
- 12 Nov 2026
Key data as of 3 Nov 2026
Latest signals on PHVS
- Analyst
PHVS upgraded to Buy by B of A Securities as deucrictibant Phase 3 data reinforces HAE prophylaxis potential; analyst maintains $44 price target.
- Cost to Borrow
PHVS cost to borrow surges to 0.82%, up 168% over the past week, as retail attention and options traders flip bullish on the oral HAE candidate.
- Alt Data
PHVS retail attention surges 6.6 standard deviations above its 90-day average, per Wikipedia views and ORTEX stock page traffic, as of October 19.
PHVS news and analysis
RSSNo long-form analysis yet for PHVS. Pulse alerts and the live data picture are available on ORTEX.
Open PHVS on ORTEX →Want the live picture for PHVS?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PHVS — free to start on ORTEX.
Sign up for free →Open PHVS on ORTEX